Company intelligence / Profile preview

Peregrine Holdings

Tustin, California, United States

Ownership: Private
Development stage: Other

Overview

Pursued clinical programs with bavituximab in second-line non-small cell lung cancer (Phase II trial with data discrepancies reported in 2012) and Cotara for glioblastoma; company no longer active as standalone entity[1][2].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

varisacumab

Unknown

Beyond the preview

Go deeper on Peregrine Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peregrine Holdings.

Explore the full profile